Intuitive Surgical (ISRG) is witnessing strong momentum, with its shares having rallied 26.4% year to date compared with 6.1% growth of the industry. The S&P 500 composite has risen 17.6% during the said time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Intuitive Surgical Inc., a Sunnyvale, CA-based company, designs, manufactures and markets the da Vinci surgical system, Ion endoluminal ...

Intuitive Surgical (NASDAQ:ISRG) stock is on the move Thursday after the company’s shares were given a price target increase by Barclays analysts.Barclays analyst Matt Miksic increased the firm’s price target for ISRG stock from $430 per share to $490 per share. That’s a potential upside of 17.5% over its prior closing price. It’s also above the analysts’ consensus price prediction of $426.53 per share.The Barclays analyst reiterated the firm’s “overweight” rating for ISRG stock alongside that price target ...

Intuitive Surgical, Inc. (ISRG) will report second-quarter 2024 earnings on Jul 18. The Zacks Consensus Estimate for sales and earnings is pegged at $1.97 billion and $1.53 per share, respectively. Earnings per share estimates for ISRG have remained stable at $6.26 and $7.32 for 2024 and 2025, respectively, over the past 60 days.Estimate MovementImage Source: Zacks Investment ResearchIn the last reported quarter, ISRG delivered an earnings surprise of 8.84%. Its earnings beat estimates in each of the traili ...

MARIOS07/iStock via Getty Images Introduction Intuitive Surgical's (NASDAQ:ISRG) stock has rallied another 17% since my Q1 earnings preview in April. I recommended a "buy," noting the company's dominance in robotic surgery, growth, and impressive financial performance. To no surprise, the company delivered solid Q1 results, posting revenues of $1.89 billion and EPS of $1.51, both beating estimates. The article below looks ahead to Q2 earnings. Intuitive Surgical Eyes Revenue Boost with da Vinci 5 Upgrad ...

These two companies have done it before -- and can do it again.Turning $1,000 into $4,000 in a decade by investing in stocks (or anything else) is no small feat. It requires a compound annual growth rate (CAGR) of almost 15%. For reference, the S&P 500's CAGR in the past decade is 13.1%, and that's very high by historical standards. So, this task demands that an investor beat the market by some margin.Though equities that can pull that off aren't easy to find, they exist. Let's consider two stocks that migh ...

文章核心观点 - 公司是医疗器械行业中的机器人手术领导者,其达芬奇手术系统在全球范围内拥有近8000台安装基础 [6] - 公司在2024年第一季度表现出色,收入同比增长12%,净利润大幅增长,达芬奇手术量也有16%的同比增长 [7] - 公司新一代达芬奇手术系统(dV5)的推出将进一步提升公司的收入和利润 [8] - 公司的付费模式正在被医院更广泛地采用,有利于医疗机构扩大手术能力 [8] - 公司的高增长表现与同行业其他公司相比更为出色 [8] 行业和公司分析 行业分析 - 医疗器械行业整体表现相对较弱,但预计第二季度行业整体盈利增长将较为乐观 [2][3][4] - 公司在同行业中的估值水平较高,但增长潜力也较强 [21][23] 公司分析 - 公司在手术机器人领域处于领先地位,拥有近8000台安装基础 [6] - 公司2024年第一季度业绩表现出色,收入和利润均有大幅增长 [7] - 公司新一代达芬奇手术系统的推出将进一步提升公司业绩 [8] - 公司的付费模式正在被医院更广泛采用,有利于扩大手术能力 [8] - 公司的增长表现优于同行业其他公司 [8] - 公司估值水平较高,但增长潜力也较强 [21][23]

Intuitive Surgical, Inc. (ISRG) is well-poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by solid results in the last few quarters and its progress on the Artificial Intelligence (AI) front, is expected to contribute further. However, procedure adoption risks and stiff competition persist.Shares of this Zacks Rank #2 (Buy) company have risen 31.8% year to date compared with the industry’s 2.9% growth. The S&P 500 Index has gained 17.7% during the same time fr ...

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $442.30, moving -0.5% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop of 0.13%, and the technology-dominated Nasdaq saw an increase of 0.14%.Shares of the company have appreciated by 6.25% over the course of the past month, outperforming the Medical sector's loss of 1.99% and the S&P 500's gain of 4.34%.Investors will be eagerly watching for the p ...

Shares of Intuitive Surgical (ISRG) have risen more than 10% in the past month, outperforming the Zacks Medical - Instruments industry’s growth of 0.7% and the broader Zacks Medical sector’s return of 1.6%. The company continued to touch new 52-week highs in the last month and made an all-time high of $448.10 on Jul 1, before declining almost 1.9%. We believe that the recent momentum will continue this month as investors remain upbeat about Intuitive Surgical’s robot-based da Vinci surgical system, which ha ...

文章核心观点 - 医疗保健行业在不同经济周期中都能保持稳定 [1] - 医疗保健公司提供生命救助药品和设备等必需品,不受经济环境影响 [2] - 长期投资者可将优质医疗保健公司纳入投资组合 [2] 行业和公司研究总结 Intuitive Surgical - 公司制造和销售机器人手术系统,已在全球范围内用于约1500万例手术 [4] - 公司收入主要来自手术器械和配件,而非系统销售 [5] - 公司提供多种服务支持客户,如软件、培训和维护合同 [6] - 公司营收和利润增长迅速,现金流和财务状况良好 [6][7][8] Eli Lilly - 公司是一家顶级制药公司,拥有稳定的股息支付历史 [9][10] - 公司拥有多个畅销药品,如糖尿病药物、抗癌药和银屑病药物 [11] - 公司新药物Zepbound和Mounjaro销售强劲 [12] - 公司正等待其阿尔茨海默病药物donanemab获批,市场前景广阔 [13][14]